Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis

Author: Herk-Sukel Myrthe  

Publisher: Springer Publishing Company

ISSN: 0167-6806

Source: Breast Cancer Research and Treatment, Vol.122, Iss.3, 2010-08, pp. : 843-851

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content